Who was studied, and how
Two numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 1 other study
375people in the Effect and Safety of Semaglutide 2.4 mg Once-weekly on Weight Management in Subjects With Overweight or Obesity. trial, from 2020
of them with obesity, in this paper
Among Chinese participants, the trial randomly assignedassigned by chance
semaglutide 2.4 mg
placebo
May have lowered body weight from baseline to Week 44−8.30
May have raised proportion of participants who achieved ≥5% reduction in body weight16×
randomised · one subgroupthe abstract, start to end
… placebo (estimated treatment difference -8.3%; 95% confidence interval [CI] …
… placebo (85.4% vs. 26.8%): odds ratio 16.1; 95% CI 8.4, 30.9; p < 0.0001.
← favours treatmentfavours comparator →
could be chanceChange in mean body weight from baseline to Week 44semaglutide 2.4 mg vs placebo, in Chinese participants
−8.3−10.2 to −6.40
Proportion of participants who achieved ≥5% reduction in body weight from baselinesemaglutide 2.4 mg vs placebo, in Chinese participants
OR 16.18.40–30.9
GLP-1 receptor agonistsBody weight & composition
GLP-1 receptor agonists × body weight & compositionhelps?replicated
unlikelylikely
0.900.90 without it
← favours comparatorfavours treatment →
1 / 6